Applied DNA Sciences Full Year 2023 Earnings: Revenues Disappoint

Applied DNA Sciences (NASDAQ:APDN) Full Year 2023 Results

Key Financial Results

• Revenue: US$13.4m (down 26% from FY 2022).
• Net loss: US$9.95m (loss widened by 19% from FY 2022).
• US$0.76 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Mdx Testing Services segment contributing a total revenue of US$11.3m (84% of total revenue). Notably, cost of sales worth US$7.83m amounted to 59% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$12.8m (77% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$1.01m. Explore how APDN's revenue and expenses shape its earnings.

Applied DNA Sciences shares are down 7.2% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Applied DNA Sciences that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.